Catherine Schulte

Stock Analyst at Baird

(0.52)
# 1652
Out of 5,291 analysts
131
Total ratings
50.50%
Success rate
9.80%
Average return
18 Stocks
Name Action Price Target Current % Upside Ratings Updated
A
Agilent Technologies
Maintains: Outperform
161 159
116.29 36.73% 15 Feb 27, 2025
Maravai LifeSciences
Downgrades: Neutral
9 3
2.29 31% 5 Feb 26, 2025
Bio-Techne
Downgrades: Neutral
88 68
58.37 16.5% 9 Feb 19, 2025
Qiagen
Downgrades: Neutral
52 42
39.64 5.95% 3 Feb 19, 2025
Mettler-Toledo Intl
Maintains: Neutral
1362 1369
1167.86 17.22% 7 Feb 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
268 258
202.41 27.46% 7 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
70 67
43.06 55.6% 13 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
27 26
16.06 61.89% 10 Oct 28, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
632 622
491.77 26.48% 25 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
182 165
n/a n/a 6 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
42 38
20.01 89.91% 7 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
56 33
39.49 -16.43% 3 Nov 21, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
4 2
n/a n/a 1 Jun 3, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
335 281
79 255.7% 6 Sep 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
21
n/a n/a 1 May 26, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 29
n/a n/a 5 Apr 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
208 217
363.16 -40.25% 7 Oct 30, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
17 20
139.43 -85.66% 1 Jun 28, 2018